NYSE:ABBV - AbbVie Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$99.57 +0.82 (+0.83 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$99.57
Today's Range$98.00 - $99.8650
52-Week Range$69.38 - $125.86
Volume20.81 million shs
Average Volume11.19 million shs
Market Capitalization$158.01 billion
P/E Ratio17.78
Dividend Yield3.86%
Beta1.61

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10
Phone847-932-7900

Debt

Debt-to-Equity Ratio8.70
Current Ratio1.20
Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio17.78
Forward P/E Ratio12.77
P/E Growth0.93

Sales & Book Value

Annual Sales$28.22 billion
Price / Sales5.60
Cash Flow$6.5853 per share
Price / Cash15.12
Book Value$3.19 per share
Price / Book31.21

Profitability

EPS (Most Recent Fiscal Year)$5.60
Net Income$5.31 billion
Net Margins21.55%
Return on Equity186.47%
Return on Assets14.42%

Miscellaneous

Employees29,000
Outstanding Shares1,586,880,000

AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, June 14th. Shareholders of record on Friday, July 13th will be given a dividend of $0.96 per share on Wednesday, August 15th. This represents a $3.84 annualized dividend and a yield of 3.86%. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie announced that its board has authorized a stock repurchase plan on Friday, February 16th 2018, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings data on Thursday, April, 26th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.79 by $0.08. The business had revenue of $7.93 billion for the quarter, compared to analysts' expectations of $7.60 billion. AbbVie had a return on equity of 186.47% and a net margin of 21.55%. AbbVie's revenue was up 21.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.28 earnings per share. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $7.66-7.76 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.53.

What price target have analysts set for ABBV?

17 brokers have issued twelve-month price objectives for AbbVie's shares. Their predictions range from $65.61 to $157.00. On average, they anticipate AbbVie's stock price to reach $104.6150 in the next twelve months. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:
  • 1. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well based on strong demand trends, despite new competition. Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. AbbVie’s shares have outperformed the industry in the past year supported by a series of positive news including promising data from several pivotal studies, regulatory approvals, including its competitive HCV medicine Mavyret and two approvals for Imbruvica and settlement of its Humira patent disputes with Amgen. In fact. Mavyret has become a major growth driver for AbbVie in a short time on the market. Also, several pivotal data readouts and regulatory milestones are expected in 2018. However, Viekira’s sales continue to be hurt by intensifying competition." (3/20/2018)
  • 2. BMO Capital Markets analysts commented, "On its fiscal 3Q18 earnings call, MDT said it does not expect the first-in- human use of its surgical robot in the next couple of months as the company had intended. Recall, MDT had previously said that it expected to be in clinical use by end of its fiscal 2018." (2/15/2018)

Are investors shorting AbbVie?

AbbVie saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 43,501,770 shares, an increase of 80.5% from the May 15th total of 24,096,693 shares. Based on an average daily volume of 14,776,682 shares, the short-interest ratio is presently 2.9 days. Currently, 2.7% of the shares of the company are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 64)
  • Mr. William J. Chase, Exec. VP & CFO (Age 50)
  • Mr. Michael E. Severino, Exec. VP of R&D and Chief Scientific Officer (Age 52)
  • Ms. Laura J. Schumacher, Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. Carlos Alban, Exec. VP of Commercial Operations (Age 55)

Has AbbVie been receiving favorable news coverage?

Press coverage about ABBV stock has been trending somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AbbVie earned a coverage optimism score of 0.13 on Accern's scale. They also gave news stories about the company an impact score of 45.80 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.30%), Northern Trust Corp (1.36%), Wells Fargo & Company MN (0.80%), Legal & General Group Plc (0.48%), LSV Asset Management (0.39%) and Schwab Charles Investment Management Inc. (0.38%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which major investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Federated Investors Inc. PA, BlackRock Inc., Wells Fargo & Company MN, Prudential Financial Inc., Swiss National Bank, Legal & General Group Plc and Northern Trust Corp. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which major investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Mackay Shields LLC, Rock Springs Capital Management LP, SG Americas Securities LLC, Dimensional Fund Advisors LP, Caisse DE Depot ET Placement DU Quebec, Franklin Resources Inc. and ING Groep NV. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $99.57.

How big of a company is AbbVie?

AbbVie has a market capitalization of $158.01 billion and generates $28.22 billion in revenue each year. The company earns $5.31 billion in net income (profit) each year or $5.60 on an earnings per share basis. AbbVie employs 29,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  708 (Vote Outperform)
Underperform Votes:  428 (Vote Underperform)
Total Votes:  1,136
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AbbVie (NYSE:ABBV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
17 Wall Street analysts have issued ratings and price targets for AbbVie in the last 12 months. Their average twelve-month price target is $104.6150, suggesting that the stock has a possible upside of 5.07%. The high price target for ABBV is $157.00 and the low price target for ABBV is $65.61. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.122.382.402.60
Ratings Breakdown: 4 Sell Rating(s)
7 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $104.6150$115.6667$120.8571$99.2143
Price Target Upside: 5.07% upside13.98% upside1.21% upside3.99% upside

AbbVie (NYSE:ABBV) Consensus Price Target History

Price Target History for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/11/2018ArgusLower Price TargetBuy ➝ Buy$145.00 ➝ $130.00LowView Rating Details
6/6/2018Credit Suisse GroupSet Price TargetSell$89.00LowView Rating Details
6/1/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$125.86 ➝ $66.62LowView Rating Details
5/30/2018Deutsche BankDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61MediumView Rating Details
5/24/2018Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHighView Rating Details
5/23/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$81.00 ➝ $78.00LowView Rating Details
4/30/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$131.00 ➝ $110.00HighView Rating Details
4/13/2018Jefferies Financial GroupSet Price TargetBuy$122.00LowView Rating Details
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$120.00 ➝ $102.00LowView Rating Details
3/26/2018Bank of AmericaSet Price TargetHold$120.00HighView Rating Details
1/29/2018Evercore ISIReiterated RatingBuy$144.00LowView Rating Details
1/29/2018SunTrust BanksBoost Price TargetBuy ➝ Average$157.00LowView Rating Details
1/29/2018Leerink SwannDowngradeOutperform ➝ Market Perform$127.00MediumView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/13/2017UBS GroupReiterated RatingNeutralN/AView Rating Details
10/11/2017CowenUpgradeMarket Perform ➝ Outperform$91.17 ➝ $105.00N/AView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016CitigroupDowngradeBuy ➝ Neutral$60.00N/AView Rating Details
9/8/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$75.00 ➝ $73.00N/AView Rating Details
9/1/2016Raymond JamesInitiated CoverageOutperform$82.00N/AView Rating Details
(Data available from 6/17/2016 forward)

Earnings

AbbVie (NYSE:ABBV) Earnings History and Estimates Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Earnings Estimates

2018 EPS Consensus Estimate: $7.82
2019 EPS Consensus Estimate: $8.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$1.79$1.85$1.82
Q2 20184$1.91$2.03$1.97
Q3 20184$1.93$2.15$2.01
Q4 20184$1.88$2.19$2.03
Q1 20192$2.04$2.06$2.05
Q2 20192$2.04$2.20$2.12
Q3 20192$2.07$2.26$2.17
Q4 20192$2.20$2.31$2.26

AbbVie (NYSE ABBV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2018$1.96N/AView Earnings Details
4/26/2018Q1 2018$1.79$1.87$7.6004 billion$7.9340 billionViewN/AView Earnings Details
1/26/2018Q4 2017$1.44$1.48$7.5339 billion$7.7390 billionViewListenView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.0010 billion$6.9950 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.9301 billion$6.9440 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.2620$1.28$6.4871 billion$6.5380 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AbbVie (NYSE:ABBV) Dividend Information

AbbVie pays an annual dividend of $3.84 per share, with a dividend yield of 3.86%. ABBV's next quarterly dividend payment will be made on Wednesday, August 15. The company has grown its dividend for the last 45 consecutive years and is increasing its dividend by an average of 15.50% each year. AbbVie pays out 68.57% of its earnings out as a dividend.
Next Dividend:8/15/2018
Annual Dividend:$3.84
Dividend Yield:3.86%
Dividend Growth:15.50% (3 Year Average)
Payout Ratio(s):68.57% (Trailing 12 Months of Earnings)
49.23% (Based on This Year's Estimates)
43.49% (Based on Next Year's Estimates)
58.31% (Based on Cash Flow)
Track Record:45 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE:ABBV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/14/2018quarterly$0.963.89%7/13/20188/15/2018
2/15/2018quarterly$0.963.36252189141856%4/12/20184/13/20185/15/2018
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

AbbVie (NYSE ABBV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 69.50%
Insider Trading History for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

AbbVie (NYSE ABBV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Carlos AlbanEVPSell83,574$114.49$9,568,387.26133,026View SEC Filing  
3/1/2018Laura J SchumacherInsiderSell25,000$117.85$2,946,250.00123,317View SEC Filing  
3/1/2018William J ChaseCFOSell70,928$117.18$8,311,343.04203,391View SEC Filing  
2/28/2018Richard A GonzalezChairmanSell8,280$117.88$976,046.40321,292View SEC Filing  
2/28/2018Robert A MichaelVPSell4,294$119.43$512,832.4211,170View SEC Filing  
2/28/2018Timothy J RichmondSVPSell18,129$118.67$2,151,368.4335,717View SEC Filing  
2/20/2018Robert A MichaelVPSell992$120.31$119,347.52View SEC Filing  
12/18/2017Timothy J RichmondSVPSell87,040$98.45$8,569,088.00113,118View SEC Filing  
12/15/2017Laura J SchumacherInsiderSell145,510$96.71$14,072,272.10View SEC Filing  
11/21/2017Richard A GonzalezChairmanSell218,193$94.01$20,512,323.93492,030View SEC Filing  
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77114,922View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.0081,287View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.0010,007View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.0093,099View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00469,623View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98342,353View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00342,353View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.0015,498View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.0096,074View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00160,545View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00187,625View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15349,462View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00209,043View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00114,745View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00147,415View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.2816,706View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.7926,078View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00369,113View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00178,970View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00144,138View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18260,438View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46624,374View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00338,421View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76149,444View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.0068,204View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.1644,615View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00199,238View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.3079,064View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80395,403View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.7585,828View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38205,138View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56180,068View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.3266,703View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.7064,279View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.4164,237View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AbbVie (NYSE ABBV) News Headlines

Source:
DateHeadline
$8.24 Billion in Sales Expected for AbbVie Inc (ABBV) This Quarter$8.24 Billion in Sales Expected for AbbVie Inc (ABBV) This Quarter
www.americanbankingnews.com - June 17 at 5:02 AM
AbbVie Inc (ABBV) Sees Large Growth in Short InterestAbbVie Inc (ABBV) Sees Large Growth in Short Interest
www.americanbankingnews.com - June 16 at 1:20 AM
AbbVie: Growth And Dividend In One PackageAbbVie: Growth And Dividend In One Package
seekingalpha.com - June 15 at 3:19 PM
Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins ApprovalsPharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
finance.yahoo.com - June 15 at 3:19 PM
AbbVie Inc (ABBV) Expected to Announce Earnings of $1.97 Per ShareAbbVie Inc (ABBV) Expected to Announce Earnings of $1.97 Per Share
www.americanbankingnews.com - June 15 at 3:10 AM
AbbVie Declares Quarterly DividendAbbVie Declares Quarterly Dividend
www.prnewswire.com - June 14 at 8:52 PM
AbbVie Inc (ABBV) Plans Quarterly Dividend of $0.96AbbVie Inc (ABBV) Plans Quarterly Dividend of $0.96
www.americanbankingnews.com - June 14 at 7:42 PM
AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018
www.streetinsider.com - June 13 at 3:19 PM
Humiras Sales Will Decline -- and Its Fantastic News for AbbVieHumira's Sales Will Decline -- and It's Fantastic News for AbbVie
finance.yahoo.com - June 13 at 3:19 PM
E-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage DisordersE-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage Disorders
www.bizjournals.com - June 12 at 3:16 PM
AbbVie Inc (ABBV) Given Consensus Rating of "Hold" by BrokeragesAbbVie Inc (ABBV) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 11 at 3:30 PM
Abbvie/Roches Leukemia Drugs Combination Gets FDA ApprovalAbbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
finance.yahoo.com - June 11 at 3:09 PM
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the SpaceJAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
finance.yahoo.com - June 11 at 3:09 PM
Abbvie/Roche's Leukemia Drugs Combination Gets FDA ApprovalAbbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
finance.yahoo.com - June 11 at 3:09 PM
AbbVie (ABBV) Price Target Lowered to $130.00 at ArgusAbbVie (ABBV) Price Target Lowered to $130.00 at Argus
www.americanbankingnews.com - June 11 at 12:23 PM
3 Things In Biotech, June 9: AbbVie Rules The CLL Roost3 Things In Biotech, June 9: AbbVie Rules The CLL Roost
seekingalpha.com - June 10 at 3:18 PM
3 Reasons to Expect Smooth Sailing for AbbVies Mission-Critical Candidate3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
www.msn.com - June 10 at 3:18 PM
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
finance.yahoo.com - June 10 at 3:18 PM
Pharma Stock Roundup: Merck, Eli Lilly, AbbVie And MorePharma Stock Roundup: Merck, Eli Lilly, AbbVie And More
www.benzinga.com - June 9 at 5:01 AM
AbbVie (ABBV) Confirms FDA Approval of VENCLEXTA in Combination with Rituximab for Treatment of CLL or SLLAbbVie (ABBV) Confirms FDA Approval of VENCLEXTA in Combination with Rituximab for Treatment of CLL or SLL
www.streetinsider.com - June 9 at 5:01 AM
FDA grants full approval for AbbVie and Roches venetoclax for CLL & SLLFDA grants full approval for AbbVie and Roche's venetoclax for CLL & SLL
seekingalpha.com - June 8 at 3:13 PM
AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior TherapyAbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy
finance.yahoo.com - June 8 at 3:13 PM
Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for OlumiantPharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
finance.yahoo.com - June 8 at 3:13 PM
The 30+1 Portfolio: An Average Investors Reasoning For Buying A Stock - AbbVie, AbsolutelyThe 30+1 Portfolio: An Average Investor's Reasoning For Buying A Stock - AbbVie, Absolutely
seekingalpha.com - June 7 at 3:13 PM
[$$] Big Pharmas Tempting Payouts[$$] Big Pharma's Tempting Payouts
finance.yahoo.com - June 7 at 3:13 PM
FY2020 EPS Estimates for AbbVie Inc. (ABBV) Raised by AnalystFY2020 EPS Estimates for AbbVie Inc. (ABBV) Raised by Analyst
www.americanbankingnews.com - June 7 at 8:56 AM
AbbVie (ABBV) Given a $89.00 Price Target at Credit Suisse GroupAbbVie (ABBV) Given a $89.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - June 7 at 7:26 AM
More Thoughts On AbbVies Rova-T ImplosionMore Thoughts On AbbVie's Rova-T Implosion
seekingalpha.com - June 6 at 3:20 PM
Abbvies (ABBV) Upadacitinib Fifth RA Study Data PositiveAbbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
finance.yahoo.com - June 6 at 3:20 PM
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data PositiveAbbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
finance.yahoo.com - June 6 at 3:20 PM
AbbVie Inc. Expected to Post FY2019 Earnings of $9.07 Per Share (ABBV)AbbVie Inc. Expected to Post FY2019 Earnings of $9.07 Per Share (ABBV)
www.americanbankingnews.com - June 6 at 8:44 AM
UPDATE: AbbVie (ABBV) Reports Upadacitinib Monotherapy Meets All Primary & Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 StudyUPDATE: AbbVie (ABBV) Reports Upadacitinib Monotherapy Meets All Primary & Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study
www.streetinsider.com - June 5 at 3:13 PM
IRICoR and Université de Montréal Enter into Research Collaboration with AbbVie to Discover Tumor-Specific NeoantigensIRICoR and Université de Montréal Enter into Research Collaboration with AbbVie to Discover Tumor-Specific Neoantigens
www.bizjournals.com - June 5 at 3:13 PM
AbbVies upadacitinib successful in another late-stage RA studyAbbVie's upadacitinib successful in another late-stage RA study
seekingalpha.com - June 5 at 3:13 PM
Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid ArthritisUpadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
finance.yahoo.com - June 5 at 3:13 PM
AbbVies rheumatoid arthritis drug succeeds in late-stage studyAbbVie's rheumatoid arthritis drug succeeds in late-stage study
finance.yahoo.com - June 5 at 3:13 PM
AbbVie (ABBV) Announces Final Results of Tender OfferAbbVie (ABBV) Announces Final Results of Tender Offer
www.streetinsider.com - June 4 at 3:05 PM
Biotech Bio Series #3: Should You Buy The Dip On AbbVie?Biotech Bio Series #3: Should You Buy The Dip On AbbVie?
seekingalpha.com - June 4 at 3:05 PM
AbbVie Announces Final Results of Tender OfferAbbVie Announces Final Results of Tender Offer
finance.yahoo.com - June 4 at 3:05 PM
Todays Research Reports on Trending Tickers: AbbVie and TherapeuticsMDToday's Research Reports on Trending Tickers: AbbVie and TherapeuticsMD
finance.yahoo.com - June 4 at 3:05 PM
Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)
www.prnewswire.com - June 3 at 11:13 AM
Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenströms Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab AlonePhase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone
finance.yahoo.com - June 2 at 5:01 AM
How Novartis, Insurers Are Taking Wind Out Of AbbVie's SalesHow Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
finance.yahoo.com - June 1 at 3:13 PM
Piper Jaffray Companies Lowers AbbVie (ABBV) to NeutralPiper Jaffray Companies Lowers AbbVie (ABBV) to Neutral
www.americanbankingnews.com - June 1 at 3:06 PM
Brokers Issue Forecasts for AbbVie Inc.s FY2018 Earnings (ABBV)Brokers Issue Forecasts for AbbVie Inc.'s FY2018 Earnings (ABBV)
www.americanbankingnews.com - June 1 at 6:42 AM
Traders Irate as Computer Gave Wrong Price in AbbVie TenderTraders Irate as Computer Gave Wrong Price in AbbVie Tender
www.msn.com - June 1 at 5:16 AM
Traders Are Furious After Computer Botches Stock SaleTraders Are Furious After Computer Botches Stock Sale
finance.yahoo.com - June 1 at 5:16 AM
Traders Irate as Computer Spits Out Wrong Price in AbbVie TenderTraders Irate as Computer Spits Out Wrong Price in AbbVie Tender
www.msn.com - May 31 at 3:01 PM
AbbVie (ABBV) Lowered to "Underperform" at Deutsche BankAbbVie (ABBV) Lowered to "Underperform" at Deutsche Bank
www.americanbankingnews.com - May 31 at 2:07 PM
UPDATE: AbbVie (ABBV) Updates Preliminary Results of Tender Offer; Expects to Acquire 72.8M Shares at $103 Per ShareUPDATE: AbbVie (ABBV) Updates Preliminary Results of Tender Offer; Expects to Acquire 72.8M Shares at $103 Per Share
www.streetinsider.com - May 31 at 5:28 AM

SEC Filings

AbbVie (NYSE:ABBV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AbbVie (NYSE:ABBV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AbbVie (NYSE ABBV) Stock Chart for Sunday, June, 17, 2018

Loading chart…

This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.